Clostridium difficile (C. difficile) is a type of bacterium that lives in people’s guts. When this bacterium grows in number, it can cause an infection, C. difficile infection (CDI) that can be mild, moderate or severe. Occasionally, after initial treatment with antibiotics, the infection can re-occur, and the more times the infection re-occurs, the more likely is this to happen again. When infection happens for second and subsequent times, treatment options become more limited and less effective. Symptoms of CDI include watery diarrhoea, painful stomach cramps, dehydration, loss of appetite, weight loss.
RBX-2660 is a therapy under development for recurrent CDI. It is a non-antibiotic therapy that consists of human-derived microorganisms (microbiota suspension). It is administered directly into the patient’s intestine through the rectum as an enema. RBX-2660 has the potential to treat patients re-infected by C. difficile that currently have limited treatment options available and are at risk of serious health consequences.
Baloxavir marboxil is the first new flu medication to be developed within the last 20 years. It works in a different way to existing flu medications by blocking a specific process which influenza viruses use to multiply within the body. There is evidence that this medication may be effective in people for whom existing flu medicines (oseltamivir) do not work. Additionally, only one dose of baloxavir marboxil is needed whereas existing flu medications need to be taken over several days. If licenced, baloxavir marboxil may offer an additional treatment option for patients with influenza A or B infection and for people who have suspected oseltamivir-resistant influenza.